Plain English Summary
Background and study aims
Complications of cancer and its treatments are common. Many patients will experience side effects following chemotherapy, radiotherapy or immunological therapies. These lead to morbidity and mortality as well as resource utilisation in communities and hospitals. Complications of cancer and its treatments are predictable (fever, diarrhoea, skin reactions and drug specific effect). Stressed patients, family and friends might not always recognize the need to seek help.
The aim of this study is to show whether patients undergoing treatment for cancer can actively make sure that their treatment is safe by using checklists.
Who can participate?
Adults with cancer, along with one family or friend per patient
What does the study involve?
All participants will be given a smartphone application containing a checklist for common side effects of cancer treatment. They use the app for 60 days and complete questionnaires every 30 days
What are the possible benefits and risks of participating?
Participants may benefit from participating as they might feel extra security after checking for side effects and sharing these with a friend or family member.
Patients will be encouraged to contact health services if they experience side effects. Therefore, a possible risk of participating is that this could lead to over-treatment in some cases.
Where is the study run from?
Betsi Cadwaladr University Health Board, North Wales (UK)
When is the study starting and how long is it expected to run for?
January 2018 to May 2019
Who is funding the study?
iGrant from Tenovus Cancer Care (UK)
Who is the main contact?
Dr Christian Subbe
Prospective pilot study of a smart phone application for patients undergoing treatment for cancer
Usage of electronic checklists tailored to the needs of patients with cancer improves reliability and timelines of engagement with their multi-disciplinary team. Earlier diagnosis and treatment of common complications of cancer, chemo- and radio-therapy will lessen the impact on patient related outcome measures and resource utilization.
Ethics Board Bangor, 22/06/2018, 18/WA/0213
Interventional non-randomised feasibility study
Primary study design
Secondary study design
Non randomised study
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Cancer (solid tumours or haematological)
All participants will receive a smartphone application containing a checklist of common side effects of cancer. Participants will be asked to use this app for 60 days and will complete questionnaires every 30 days.
Primary outcome measure
Usage of application, assessed by number of completed checklists at 60 days from inclusion
Secondary outcome measures
1. Number of appointments during the study period of 60 days, assessed by questionnaires to General Practitioners and assessment of the hospital patient administration system at 60 days from inclusion
2. Number of days in hospital during the study period of 60 days, assessed by review of patient administration system at 60 days from inclusion
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Aged 18 years or older
2. Cancer patient (solid tumour or haematological cancer) and their families
3. Resident of North Wales
4. Under the care of the North Wales Cancer Centre
5. Receiving bestsupportive care, chemotherapy, radiotherapy or immunotherapy
6. Owns and able to use smartphone
7. Provide informed consent
The families or friends (one per patient) of the patients will also be invited to participate:
1. Owns and able to use a smartphone
2. Provide informed consent
Target number of participants
50 intervention, 50 control, 50 next of kin / friends
Participant exclusion criteria
1. On an end-of-life pathway
2. Inability to consent
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Trial participating centre
Ysbyty Glan Clwyd
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Publication intended in July 2019, after completion of the trial
IPD sharing statement:
The datasets generated during and/or analysed during the current study are not expected to be made available due to potential commercial sensitivities.
Intention to publish date
Participant level data
Not expected to be available
Basic results (scientific)